Cambridge university researchers have analysed the impact of using point-of-care testing at Addenbrooke's hospital.
Rapid coronavirus test speeds up access to urgent care and will free up beds ahead of winter
The SAMBA II diagnostic device cuts COVID-19 test result times from over 24 hours to just two hours.
First study of SAMBA devices on hospital wards finds patient time on COVID ‘holding wards’ was almost halved.
Researchers say faster tests helped free up beds and expedite access to life-saving treatments such as organ transplants – and might make all the difference later this year.
The first analysis of a new point-of-care “nucleic acid test” for SARS-CoV-2 in a UK hospital setting shows these machines dramatically reduce time spent on COVID-19 ‘holding’ wards – allowing patients to be treated or discharged far quicker than with current lab testing set-ups.
The rapid diagnostic capability of SAMBA II devices – an average of 2.6 hours compared with 26.4 hours for standard lab tests – led to an increased availability of ‘isolation rooms’ needed for infected patients, as well as fewer hospital bay closures.
University of Cambridge researchers behind the new study, currently a pre-print and awaiting peer-review, say that the time and hospital capacity spared by these devices will be “critical as we move towards autumn and winter”.
The SAMBA II machine was developed by a University spinout company, Diagnostics in the Real World, and deployed for trials in Addenbrooke’s Hospital, part of Cambridge University Hospitals NHS Foundation Trust (CUH).
For more information visit: CUH News
Published June 3, 2020
Trial results published by Cambridge researchers earlier this year and involving patients at Addenbrooke’s Hospital are helping to set new global standards…
A senior Addenbrooke’s early phase trials researcher has praised patients, staff and sponsors who backed a landmark trial which could be a “game changer” in…
Treating newly-diagnosed patients with advanced therapy leads to dramatic improvements in outcomes.